Loading...

OncoTherapy Science, Inc.

4564.T•JPX
Healthcare
Biotechnology
¥33.00
¥4.00(13.79%)

OncoTherapy Science, Inc. (4564.T) Stock Overview

Explore OncoTherapy Science, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 62.7/100

Key Financials

Market Cap9.5B
P/E Ratio-10.99
EPS (TTM)$-4.81
ROE-1.00%
Fundamental Analysis

AI Price Forecasts

1 Week$22.39
1 Month$36.96
3 Months$34.93
1 Year Target$14.29

4564.T Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of OncoTherapy Science, Inc. (4564.T) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 69.56, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $14.29.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -10.99 and a market capitalization of 9.5B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

69.56RSI (14)
1.97MACD
37.99ADX
Stats data is not available for 4564.TStats details for 4564.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 4564.TAnalyst Recommendations details for 4564.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.

CEO

Junichi Shimada

Employees

54

Headquarters

3-2-1 Sakado, Kawasaki

Founded

2005

Frequently Asked Questions

;